United States Biotechnology & Medical Research

Terns Pharmaceuticals Inc (TERN)

Track

Recent insider activity at Terns Pharmaceuticals Inc. has been characterized by consistent selling. The most recent transactions occurred on April 1, 2026, involving Chief Medical Officer Emil Kuriakose. Throughout the first quarter of 2026, CEO Amy Burroughs also executed multiple planned and proposed sales of company shares.
Ticker: TERN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Terns Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 1 Apr 2026
Value US$2,340,080.27 | Price 101.31 | Shares 92,834 (-15.0%)
Sale 1 Apr 2026
Value US$4,660,355.31 | Price 174.38 | Shares 28,556 (-44.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-02 2026-04-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
92,834 -15.0%
101.31
US$2,340,080 		92,834 -15.0% 101.31 US$2,340,080
2026-04-02 2026-04-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
28,556 -44.9%
174.38
US$4,660,355 		28,556 -44.9% 174.38 US$4,660,355
2026-03-17 2026-03-16 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
72,575 -22.5%
62.38
US$457,017 		72,575 -22.5% 62.38 US$457,017
2026-03-17 2026-03-16 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
11,813 -3.9%
46.57
US$550,081 		11,813 -3.9% 46.57 US$550,081
2026-02-18 2026-02-17 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
4,083 -1.4%
39.80
US$162,501 		4,083 -1.4% 39.80 US$162,501
2026-02-18 2026-02-17 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
8,159 -2.7%
39.22
US$319,963 		8,159 -2.7% 39.22 US$319,963
2026-02-18 2026-02-17 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
2,341 -0.8%
38.07
US$89,114 		2,341 -0.8% 38.07 US$89,114
2026-01-16 2026-01-15 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
7,521 -2.5%
37.53
US$282,230 		7,521 -2.5% 37.53 US$282,230
2026-01-16 2026-01-15 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
61,228 -17.1%
37.02
US$2,266,373 		61,228 -17.1% 37.02 US$2,266,373
2026-01-15 2026-01-15 PrS Proposed sale
3.0
AMY BURROUGHS

Director; Officer

Executive Director
97,915
37.18
US$3,640,480 		97,915 37.18 US$3,640,480
2026-01-06 2026-01-05 S Sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
71,339 -33.9%
38.10
US$2,718,230 		71,339 -33.9% 38.10 US$2,718,230
2026-01-06 2026-01-02 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
955 -1.9%
38.36
US$36,632 		955 -1.9% 38.36 US$36,632
2026-01-06 2026-01-02 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
200 -0.4%
39.60
US$7,920 		200 -0.4% 39.60 US$7,920
2025-11-05 2025-11-04 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
24,520 -100.0%
18.00
US$441,360 		24,520 -100.0% 18.00 US$441,360
2025-11-04 2025-11-04 PrS Proposed sale
3.7
JILL QUIGLEY

Director

Non-Executive Director
24,520
14.03
US$344,016 		24,520 14.03 US$344,016
2025-10-02 2025-10-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
944 -1.8%
7.85
US$7,407 		944 -1.8% 7.85 US$7,407
2025-07-03 2025-07-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
853 -1.6%
4.27
US$3,640 		853 -1.6% 4.27 US$3,640
2025-06-30 2025-06-27 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +25.0%
3.93
US$19,650 		5,000 +25.0% 3.93 US$19,650
2025-06-30 2025-06-27 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +33.3%
3.93
US$19,634 		5,000 +33.3% 3.93 US$19,634
2025-06-25 2025-06-25 PP Planned purchase
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
23,314 +98.1%
3.87
US$90,230 		23,314 +98.1% 3.87 US$90,230
2025-06-16 2025-06-16 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +50.0%
3.95
US$19,732 		5,000 +50.0% 3.95 US$19,732
2025-06-16 2025-06-13 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +100.0%
3.72
US$18,600 		5,000 +100.0% 3.72 US$18,600
2025-06-16 2025-06-13 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +inf%
3.75
US$18,750 		5,000 +inf% 3.75 US$18,750
2025-04-02 2025-04-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
952 -1.8%
2.49
US$2,366 		952 -1.8% 2.49 US$2,366
2025-01-06 2025-01-06 PrS Proposed sale
3.3
MARK J VIGNOLA

Officer

Officer
9,059
5.75
US$52,089 		9,059 5.75 US$52,089
2025-01-06 2025-01-06 PrS Proposed sale
3.7
JILL QUIGLEY

Director

Non-Executive Director
8,760
5.75
US$50,370 		8,760 5.75 US$50,370
2025-01-06 2025-01-06 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
8,760 -100.0%
5.79
US$50,758 		8,760 -100.0% 5.79 US$50,758
2025-01-06 2025-01-06 PlS Planned sale
3.3
Vignola Mark J.

Chief Financial Officer

Officer
9,059 -10.8%
5.80
US$52,500 		9,059 -10.8% 5.80 US$52,500
2025-01-06 2025-01-02 S Sale
3.7
Quigley Jill M.
Non-Executive Director
6,240 -41.6%
5.72
US$35,702 		6,240 -41.6% 5.72 US$35,702
2025-01-06 2025-01-02 S Sale
3.3
Vignola Mark J.

Chief Financial Officer

Officer
8,129 -8.8%
5.72
US$46,524 		8,129 -8.8% 5.72 US$46,524
2025-01-06 2025-01-02 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
4,481 -7.6%
5.71
US$25,607 		4,481 -7.6% 5.71 US$25,607
2024-12-09 2024-12-05 PP Planned purchase
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
15,450 +423.4%
7.15
US$110,468 		15,450 +423.4% 7.15 US$110,468
2025-02-03 2024-11-30 PP Planned purchase Jung Melita Sun

Chief Business Officer

Officer
2,250 +inf%
5.11
US$11,498 		2,250 +inf% 5.11 US$11,498
2025-02-03 2024-11-30 PP Planned purchase Burroughs Amy L.

Chief Executive Officer

Executive Director
510 +2.7%
5.11
US$2,606 		510 +2.7% 5.11 US$2,606
2024-09-17 2024-09-12 B Purchase
3.5
Lu Hongbo
Non-Executive Director
285,714 +150.0%
10.50
US$2,999,997 		285,714 +150.0% 10.50 US$2,999,997
2024-09-17 2024-09-12 B Purchase
3.5
Lu Hongbo
Non-Executive Director
190,476 +inf%
10.50
US$1,999,998 		190,476 +inf% 10.50 US$1,999,998
2024-09-12 2024-09-10 PlS Planned sale
3.3
Vignola Mark J.

Chief Financial Officer

Officer
10,000 -9.8%
11.00
US$110,000 		10,000 -9.8% 11.00 US$110,000
2024-09-10 2024-09-10 PrS Proposed sale
SEOKHO BRYAN YOON

Officer

Officer
10,000
9.12
US$91,200 		10,000 9.12 US$91,200
2024-09-10 2024-09-10 PrS Proposed sale
3.3
MARK J VIGNOLA

Officer

Officer
10,000
9.12
US$91,200 		10,000 9.12 US$91,200
2024-09-11 2024-09-09 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
17,235 -53.5%
10.00
US$172,350 		17,235 -53.5% 10.00 US$172,350
2024-09-09 2024-09-09 PrS Proposed sale
3.7
JILL QUIGLEY

Officer

Officer
8,857
7.81
US$69,173 		8,857 7.81 US$69,173
2024-08-05 2024-08-02 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
8,857 -37.1%
7.50
US$66,432 		8,857 -37.1% 7.50 US$66,432
2024-08-05 2024-08-01 S Sale
3.7
Quigley Jill M.
Non-Executive Director
6,143 -20.5%
7.68
US$47,148 		6,143 -20.5% 7.68 US$47,148
2024-07-17 2024-07-16 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
623 -0.1%
10.00
US$6,230 		623 -0.1% 10.00 US$6,230
2024-07-17 2024-07-16 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
556 -0.0%
10.00
US$5,560 		556 -0.0% 10.00 US$5,560
2024-07-17 2024-07-16 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
4,009 -0.1%
10.00
US$40,090 		4,009 -0.1% 10.00 US$40,090
2024-07-17 2024-07-16 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
623 -0.1%
10.00
US$6,230 		623 -0.1% 10.00 US$6,230
2024-07-17 2024-07-16 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
556 -0.0%
10.00
US$5,560 		556 -0.0% 10.00 US$5,560
2024-07-17 2024-07-16 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
4,009 -0.1%
10.00
US$40,090 		4,009 -0.1% 10.00 US$40,090
2024-07-17 2024-07-16 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
400 -1.3%
10.00
US$4,000 		400 -1.3% 10.00 US$4,000
2024-07-17 2024-07-15 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
6,142 -0.8%
10.00
US$61,420 		6,142 -0.8% 10.00 US$61,420
2024-07-17 2024-07-15 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
5,401 -0.3%
10.00
US$54,010 		5,401 -0.3% 10.00 US$54,010
2024-07-17 2024-07-15 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
39,433 -0.8%
10.00
US$394,330 		39,433 -0.8% 10.00 US$394,330
2024-07-17 2024-07-15 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
6,142 -0.8%
10.00
US$61,420 		6,142 -0.8% 10.00 US$61,420
2024-07-17 2024-07-15 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
5,401 -0.3%
10.00
US$54,010 		5,401 -0.3% 10.00 US$54,010
2024-07-17 2024-07-15 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
39,433 -0.8%
10.00
US$394,330 		39,433 -0.8% 10.00 US$394,330
2024-07-17 2024-07-15 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
14,365 -32.4%
10.00
US$143,660 		14,365 -32.4% 10.00 US$143,660
2024-07-15 2024-07-15 PrS Proposed sale
3.7
JILL QUIGLEY

Director; Officer

Executive Director
32,000
9.31
US$297,920 		32,000 9.31 US$297,920
2024-07-15 2024-07-15 PrS Proposed sale
2.6
OrbiMed Asia Partners III, LP

Director; Shareholder

Non-Executive Director
131,700
9.31
US$1,226,127 		131,700 9.31 US$1,226,127
2024-07-15 2024-07-15 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Director; Shareholder

Non-Executive Director
976,800
9.31
US$9,094,008 		976,800 9.31 US$9,094,008
2024-07-15 2024-07-15 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, LP

Director; Shareholder

Non-Executive Director
152,400
9.31
US$1,418,844 		152,400 9.31 US$1,418,844
2024-06-04 2024-05-31 PP Planned purchase
3.3
Vignola Mark J.

Chief Financial Officer

Officer
4,791 +5.5%
4.44
US$21,272 		4,791 +5.5% 4.44 US$21,272
2024-06-04 2024-05-31 PP Planned purchase
Yoon Seokho Bryan

COO and General Counsel

Officer
4,791 +5.5%
4.44
US$21,272 		4,791 +5.5% 4.44 US$21,272
2024-04-03 2024-04-03 PrS Proposed sale
Vivo Capital Surplus Fund VIII, L.P.

Director

Non-Executive Director
5,443
6.00
US$32,658 		5,443 6.00 US$32,658
2024-04-03 2024-04-03 PrS Proposed sale
Vivo Capital Fund VIII, L.P.

Director

Non-Executive Director
39,416
6.00
US$236,496 		39,416 6.00 US$236,496
2024-04-03 2024-04-03 PrS Proposed sale
Vivo Opportunity Fund Holdings, L.P.

Director

Non-Executive Director
136,258
6.00
US$817,548 		136,258 6.00 US$817,548
2024-04-03 2024-04-03 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
4,149 -1.5%
6.20
US$25,724 		4,149 -1.5% 6.20 US$25,724
2024-04-03 2024-04-03 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
30,047 -1.5%
6.20
US$186,291 		30,047 -1.5% 6.20 US$186,291
2024-04-03 2024-04-03 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
103,870 -2.5%
6.20
US$643,994 		103,870 -2.5% 6.20 US$643,994
2024-04-03 2024-04-02 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
3,050 -1.1%
6.65
US$20,282 		3,050 -1.1% 6.65 US$20,282
2024-04-03 2024-04-02 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
22,084 -1.1%
6.65
US$146,859 		22,084 -1.1% 6.65 US$146,859
2024-04-03 2024-04-02 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
76,346 -1.8%
6.65
US$507,701 		76,346 -1.8% 6.65 US$507,701
2024-04-03 2024-04-01 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
5,451 -1.9%
6.99
US$38,102 		5,451 -1.9% 6.99 US$38,102
2024-04-03 2024-04-01 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
39,411 -1.9%
6.99
US$275,483 		39,411 -1.9% 6.99 US$275,483
2024-04-03 2024-04-01 PlS Planned sale
2.9
Vivo Opportunity, LLC
Large shareholder
136,255 -3.1%
6.99
US$952,422 		136,255 -3.1% 6.99 US$952,422
Explore more

More insider trading research around Terns Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America